Sayna Norouzi, MD

Norouzi discussed the remaining challenges that come with having evolving treatment options and a robust patient population in IgAN.

New IgAN guidelines emphasize earlier diagnosis, lower proteinuria targets, and combination therapy to delay kidney failure and improve long-term outcomes.

FDA-approved iptacopan and pegcetacoplan offer new complement-targeted therapies for C3 glomerulopathy.

Norouzi discusses a recent review where 11 clinicians described C3G pathology and diagnosis.

On Rare Disease Day 2026, clinicians share their perspective on the evolving landscape for IgAN and C3G.

The phase 2 study of ALXN2050 in IgAN did not meet its proteinuria endpoint, with emerging safety concerns and early termination.